BLASOLUTIONINJECTION
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
EPYSQLI (eculizumab-aagh) by Samsung Bioepis is complement inhibitors [moa]. Approved for paroxysmal nocturnal hemoglobinuria, myasthenia gravis, neuromyelitis optica spectrum disorder. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EPYSQLI (eculizumab-aagh) is a monoclonal antibody complement inhibitor approved July 2024 as a biosimilar referencing SOLIRIS. It treats paroxysmal nocturnal hemoglobinuria, myasthenia gravis, and neuromyelitis optica spectrum disorder by blocking the C5 complement protein to prevent cell destruction.
Growth
Early-stage biosimilar in growth phase with modest competitive pressure (30%), offering opportunity for market expansion as awareness and adoption build.
Mechanism of Action
Complement Inhibitors
Pharmacologic Class:
Complement Inhibitor
Indications (3)
Worked on EPYSQLI at Samsung Bioepis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.